Class/mechanism: mTOR (mammalian target of rapamycin) inhibitor. mTOR inhibition by temsirolimus interferes with the ability of mTOR to phosphorylate downstream targets in the PI3 kinase/AKT pathway, such as p70S6k and the S6 ribosomal protein. Temsirolimus has also been observed to reduce levels of VEGF (vascular endothelial growth factor) and hypoxia-inducible factors HIF-1 and HIF-2 alpha.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Renal cancer
- Uterine cancer
Patient drug information
- Temsirolimus (Torisel) patient drug information (Chemocare)
- Temsirolimus (Torisel) patient drug information (UpToDate)
History of changes in FDA indication
- 5/30/2007: Initial FDA approval for the treatment of advanced renal cell carcinoma.
Also known as
Precise Name: temsirolimus (RXCUI 657797)
|CCI 779||Torisel||cell cycle inhibitor 779||rapamycin analog CCI-779|